Granules India Faces USFDA Scrutiny at Gagillapur Site

11 observations issued by USFDA following facility inspection; no impact on current production or distribution reported by the company.

Reader Takeaway: Management emphasizes addressable issues, though the count of observations at a previously flagged facility warrants caution.

What just happened

Granules India Limited has completed a USFDA inspection of its finished dosage manufacturing unit in Gagillapur, Hyderabad. The inspection, conducted from October 19 to October 30, 2026, concluded with the receipt of a Form FDA 483 containing 11 observations. The company confirmed that these findings do not involve data integrity or cross-contamination issues.

Why this matters

This facility had previously received a Warning Letter from the USFDA in February 2025. While the company stated that current manufacturing and distribution remain unaffected, the accumulation of 11 observations at a site under prior regulatory watch is a key monitorable for investors assessing long-term compliance stability.

Nature of the findings

The observations primarily target procedural enhancements, including investigation protocols, change control, process and equipment qualification, visual inspection controls, and documentation practices. Management characterized the inspection as constructive and indicated that the issues are addressable through corrective and preventive actions (CAPA).

What happens next

Granules India is required to submit a comprehensive response to the USFDA within 15 business days. Investors should monitor the company’s updates regarding the acceptance of these corrective measures by the regulator and any subsequent status changes for the facility.